Literature DB >> 8832527

Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. I: Clinical applications and therapeutic effects.

T D Miale1, S Sirithorn, S Ahmed.   

Abstract

Here, we review the role of total body irradiation in the treatment of children with bone marrow transplantation, as well as alternative sources of stem cells. We were unable to demonstrate any clear superiority of TBI-containing preparative regimens, but we were able to find a few definitive reports of significantly enhanced toxicity or important variations in control of the underlying primary diseases, in comparing TBI-based regimens, with those containing only chemotherapy.

Entities:  

Mesh:

Year:  1995        PMID: 8832527     DOI: 10.1007/bf02990569

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  136 in total

1.  Teniposide, doxorubicin, melphalan, cisplatin, and total body irradiation with autologous bone marrow transplantation for advanced neuroblastoma.

Authors:  P R Lam-Po-Tang; G B McCowage; M R Vowels
Journal:  Transplant Proc       Date:  1993-10       Impact factor: 1.066

2.  Comparison of two total body irradiation regimens in allogeneic bone marrow transplantation for acute non-lymphoblastic leukemia in first remission.

Authors:  T H Kim; P B McGlave; N Ramsay; W Woods; B Bostrom; G Vercellotti; D Hurd; W Krivit; M Nesbit; R Haake
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-10       Impact factor: 7.038

Review 3.  Experimental and clinical studies of cytokine gene-modified tumor cells.

Authors:  R I Tepper; J J Mulé
Journal:  Hum Gene Ther       Date:  1994-02       Impact factor: 5.695

4.  Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease.

Authors:  J E Wagner; N A Kernan; M Steinbuch; H E Broxmeyer; E Gluckman
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

5.  Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia.

Authors:  R A Clift; C D Buckner; F R Appelbaum; G Schoch; F B Petersen; W I Bensinger; J Sanders; K M Sullivan; R Storb; J Singer
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

6.  Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies.

Authors:  W M Azevedo; F J Aranha; J V Gouvea; A C Vigorito; J F Marques; K A Eid; A M Azevedo; C A Souza
Journal:  Bone Marrow Transplant       Date:  1995-11       Impact factor: 5.483

7.  Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia.

Authors:  M Stockschläder; S Hegewisch-Becker; W Krüger; A tom Dieck; K Mross; M Hoffknecht; C Berger; B Kohlschütter; H Martin; S Peters
Journal:  Bone Marrow Transplant       Date:  1995-11       Impact factor: 5.483

Review 8.  Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.

Authors:  K G Blume; G D Long; R S Negrin; N J Chao; C Kusnierz-Glaz; M D Amylon
Journal:  Bone Marrow Transplant       Date:  1994       Impact factor: 5.483

9.  Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission.

Authors:  R P Gale; M M Horowitz; R S Weiner; R C Ash; K Atkinson; R Babu; K A Dicke; J P Klein; B Lowenberg; J Reiffers
Journal:  Bone Marrow Transplant       Date:  1995-08       Impact factor: 5.483

Review 10.  Neuroblastoma stage IV-S.

Authors:  T D Miale; K Kirpekar
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

View more
  1 in total

1.  NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: health-related quality of life, functional, and neurocognitive outcomes.

Authors:  Susan K Parsons; Sean Phipps; Lillian Sung; K Scott Baker; Michael A Pulsipher; Kirsten K Ness
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-10       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.